FRANKFURT (dpa-AFX) - Carl Zeiss Meditec shares jumped to their highest level since mid-December on Thursday. A buy recommendation from the experts at Equita contributed to a rise of 5.5 percent to 52.20 euros. During their recovery, the shares of the medical technology manufacturer tested the 50-day line, which is a popular chart indicator for the short to medium-term trend. At 53.10 euros, they peaked above it, but recently the threshold was once again on the brink of collapse.
The analyst firm Equita has given the company a "buy" recommendation with an upgrade to "buy". A target price of EUR 60 was given, which promises potential of almost 15 percent at the current level.
The private bank Hauck & Aufhäuser is clearly higher in the analyst universe with a target of 86.50 euros. Their analyst Alexander Galitsa listed Carl Zeiss Meditec among the "top picks" for 2025 at the beginning of the year. This year, the shares have gained 15 percent. This makes them the fifth-best stock in the MDax./tih/jha/